Last update: July 14, 2015

Polymyxin B Sulfate

Very Low Risk for breastfeeding


Compatible.
Not risky for breastfeeding or infant.

Antibiotic drug that is usual topically used (Dermatology, ENT and Ophthalmology)

At latest update no published data on excretion into breast milk were found.

The small dose and low absorption to the plasma in a majority of preparations that are topically used on the eye, ear or skin make a significant excretion into the milk unlikely.
Its high molecular weight makes less probable an excretion into breast milk in significant amount.

Due to a poor oral bioavailability, appearance in the infant's plasma from ingested milk is regarded as nil or scanty, except in premature infants or during the immediate neonatal period who may show an increased intestinal absorption.

Polymyxin E or Colistin with a very similar molecular structure is excreted into breast milk in non-significant amount.

It is advisable to avoid the application of creams, gels and other products for local use that would contain paraffin (mineral oil) to prevent absorption by the infant.

Alternatives

We do not have alternatives for Polymyxin B Sulfate since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Polymyxin B Sulfate is also known as


Tradenames

Main tradenames from several countries containing Polymyxin B Sulfate in its composition:

  • Blastoestimulina óvulos™. Contains other elements than Polymyxin B Sulfate in its composition
  • Cortisporin Ointment™. Contains other elements than Polymyxin B Sulfate in its composition
  • Dermisone Tri Antibiotic™. Contains other elements than Polymyxin B Sulfate in its composition
  • Fangan Plus™. Contains other elements than Polymyxin B Sulfate in its composition
  • Ginal Cent™. Contains other elements than Polymyxin B Sulfate in its composition
  • Ginkan™. Contains other elements than Polymyxin B Sulfate in its composition
  • Linfol Cicatrizante™. Contains other elements than Polymyxin B Sulfate in its composition
  • Mailen™. Contains other elements than Polymyxin B Sulfate in its composition
  • Neo Pelvicillin™. Contains other elements than Polymyxin B Sulfate in its composition
  • Neosporin™. Contains other elements than Polymyxin B Sulfate in its composition
  • Neosporin Ointment™. Contains other elements than Polymyxin B Sulfate in its composition
  • Oftalmotrim™. Contains other elements than Polymyxin B Sulfate in its composition
  • Oftalmowell™. Contains other elements than Polymyxin B Sulfate in its composition
  • Ovufem™. Contains other elements than Polymyxin B Sulfate in its composition
  • Ovumix™. Contains other elements than Polymyxin B Sulfate in its composition
  • Pentol™. Contains other elements than Polymyxin B Sulfate in its composition
  • Phonal™. Contains other elements than Polymyxin B Sulfate in its composition
  • Polysporin
  • Polytrim™. Contains other elements than Polymyxin B Sulfate in its composition
  • Pomada Antibiotica™. Contains other elements than Polymyxin B Sulfate in its composition
  • Septigyn™. Contains other elements than Polymyxin B Sulfate in its composition
  • Septilisin™. Contains other elements than Polymyxin B Sulfate in its composition
  • Tulgrasum Antibiotico™. Contains other elements than Polymyxin B Sulfate in its composition
  • Vagicural Plus™. Contains other elements than Polymyxin B Sulfate in its composition

Pharmacokinetics

Variable Value Unit
Bioavailability 0 %
Molecular weight 1750 daltons
VD 47,2 l/Kg
Tmax 2 hours
T1/2 6 hours

References

  1. AEMPS. Oftalmowell. Ficha técnica. 2013 Full text (in our servers)
  2. José de Jesús Coria Lorenzo, Alfredo Morayta Ramírez, Yetzamin Gutiérrez Muñoz. Polimixinas en la era de la multidrogorresistencia. Revista de Enfermedades Infecciosas en Pediatría 2011;25(98):66-70. 2011 Full text (in our servers)
  3. Kwa AL, Lim TP, Low JG, Hou J, Kurup A, Prince RA, Tam VH. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008 Abstract
  4. Concin N, Hofstetter G, Plattner B, Tomovski C, Fiselier K, Gerritzen K, Fessler S, Windbichler G, Zeimet A, Ulmer H, Siegl H, Rieger K, Concin H, Grob K. Mineral oil paraffins in human body fat and milk. Food Chem Toxicol. 2008 Abstract
  5. Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin. 2006 Abstract
  6. Noti A, Grob K, Biedermann M, Deiss U, Brüschweiler BJ. Exposure of babies to C15-C45 mineral paraffins from human milk and breast salves. Regul Toxicol Pharmacol. 2003 Abstract

Total visits

18,505

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche de México from Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM